Introduction {#Sec1}
============

Cardiac glycosides (CGs), including digoxin, ouabain, digitoxin, and oleandrin, are well-known Na^+^/K^+^-ATPase (NKA) inhibitors that have long been used for the treatment of congestive heart failure and arrhythmia. Despite their cardiotonic effects, the potent anticancer efficacy of CGs has been widely reported for many cancer types, including breast cancer, lung cancer, prostate cancer, melanoma, colon cancer, and leukemia, with some derivative compounds having entered clinical studies \[[@CR1], [@CR2]\].

To date, a variety of mechanisms addressing the anticancer effects of CGs have been identified, including the induction of apoptosis and cell cycle arrest, inhibition of topoisomerase II and estrogen receptor, blockage of p53 and HIF-1α protein synthesis, and the generation of reactive oxygen species, as well as the inhibition of migration and metastasis \[[@CR3]--[@CR6]\]. Interestingly, CG class compounds have been found to be immunogenic cell death inducers that promote the immunological clearance of cancer cells and increase the efficacy of anticancer drugs by modulating the immunosuppressive function of T cells \[[@CR7]\].

Our recent study demonstrated that autophagic cell death, which contributes to the cytotoxicity of digoxin and ouabain, is induced by CG compounds in human non-small cell lung cancer cells via the regulation of both the AMP-activated protein kinase (AMPK)-mediated mammalian target of rapamycin (mTOR) signaling pathway and the Src-mediated extracellular signal-regulated kinase 1/2 (ERK1/2) pathway \[[@CR6], [@CR8]\]. However, given the complexity of the AMPK and Src signaling pathways in cells \[[@CR9]--[@CR11]\], whether and how AMPK and Src signaling may cross-communicate with each other following CGs treatment remains unknown. Furthermore, as AMPK plays a pivotal role in regulating cellular energy homeostasis \[[@CR12]\], whether CGs-induced AMPK activation results from altered cancer cell metabolism is worthy of assessment.

In the present work, we found that ouabain induces the rapid activation of AMPK, which acts as an upstream regulator of the Src signaling pathway in the A549 and MCF7 cancer cell lines. Furthermore, ouabain greatly decreases mitochondrial oxidative phosphorylation (OXPHOS) but has differential effects on glycolysis in A549 and MCF7 cells. The altered cancer metabolism caused by ouabain may contribute to AMPK activation, as well as to its cancer cell cytotoxicity.

Materials and methods {#Sec2}
=====================

Antibodies and reagents {#Sec3}
-----------------------

The anti-β-actin (A1978) antibody, compound C (P5499), PP2 (P0042), and ouabain (O3125) were purchased from Sigma-Aldrich (Saint Louis, MO, USA). The anti-p-AMPKα (2535), anti-AMPKα (2532), anti-p-Src (2101), anti-Src (2108), anti-p-ERK1/2 (4370), anti-ERK1/2 (4695), anti-p-ACC (3661), anti-p-LKB1 (3482) antibodies, and horseradish peroxidase-linked secondary antibody (7074) were purchased from Cell Signaling Technology (Beverly, MA, USA). 5-Aminoimidazole-4-carboxamide-1-β-*D*-ribofuranoside (AICAR, sc-200659) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The ATPlite Luminescence Assay System (6016941) was purchased from PerkinElmer (Wolsem, MA, USA). The CycLex AMPK Kinase Assay kit (CY-1182) was purchased from MBL Company (Nagano, Japan). The XFp Cell Mito Stress Test (103010-100) and Glycolysis Stress Test kits (103017-100) were purchased from Agilent Technologies (Palo Ato, CA, USA). The Glucose Assay kit (glucose oxidase method, 180831) was purchased from Biosino Biotechnology and Science Inc (Beijing, China). The Lactate Acid Assay kit (A019-2) was purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

siRNA transfection {#Sec4}
------------------

siRNA duplexes against AMPK were synthesized by RiboBio Co., Ltd (Guangzhou, China) (si-*AMPK* \#1: sense sequence 5′-GCAGAAGTATGTAGAGCAA-3′; si-*AMPK* \#2: sense sequence 5′-ACACATGAATGCAAAGATA-3′). The silencing of genes using 10 nM RNAi duplexes was performed with Lipofectamine^TM^ RNAiMAX Reagent (13778-150, Life Technologies, Carlsbad, CA, USA) according to the manufacturer's recommendations.

Cell culture and drug treatment {#Sec5}
-------------------------------

The MCF7 cell line was maintained in DMEM (HyClone, Logan, UT, USA), while the A549 cell line was maintained in Ham's F12 medium (HyClone, Logan, UT, USA); both media were supplemented with 10% (v/v) fetal bovine serum (Life Technologies, Carlsbad, CA, USA), 100 U/mL penicillin G and 100 μg/mL streptomycin (HyClone, Logan, UT, USA). The cells were cultured in a humidified atmosphere containing 5% CO~2~ at 37 °C. Unless specifically described, the concentration for ouabain treatment in this work was 25 nM. For the inhibitors, 10 μM compound C or 10 μM PP2 was used in the cotreatment with ouabain or AICAR (0.5 mM), as indicated.

Immunoblotting (IB) analysis {#Sec6}
----------------------------

Cells were seeded at 3 × 10^5^ cells per well in 60 mm Petri dishes for 24 h and treated as indicated for different lengths of time. The cells were washed with ice-cold PBS and lysed with lysis buffer containing a protease inhibitor cocktail plus 1 mM PMSF. The protein concentration was determined by the Bradford assay. Protein extracts (30--50 μg) were separated by SDS-PAGE as described before \[[@CR6]\].

Semi-quantitative RT-PCR {#Sec7}
------------------------

Cells were seeded in six-well plates at 1.5 × 10^5^ cells/well for 24 h and then treated with 25 nM ouabain for the indicated time. RNA was extracted using TRIzol (\#15596026, Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using PrimeScript RT Master Mix (\#DRR036A, TaKaRa, Shiga, Japan). The reaction conditions used for the PCR were cycles for denaturation at 94 °C for 30 s, annealing at 65 °C for 30 s, and elongation at 72 °C for 40 s. Intensity values of the bands were determined with ImageJ software (National Institutes of Health, Bethesda, MD, USA) and normalized to the intensity of the *GAPDH* band. The sequences of the primers were as follows: *AMPK* forward primer, 5′-TTGAAACCTGAAAATGTCCTGCT-3′ and reverse primer, 5′- GGTGAGCCACAACTTGTTCTT-3′.

Measurement of AMPK activity {#Sec8}
----------------------------

Cells were seeded in six-well plates at 1.5 × 10^5^ cells/well for 24 h and then treated with 0.5 mM AICAR for 30 min or 25 nM ouabain for the indicated time. The relative AMPK activity was measured using a CycLex AMPK Kinase Assay kit according to the manufacturer's instructions. Briefly, the cells were lysed with lysis buffer, 10 μL of the cell lysate (containing 1 μg protein) was added to the microplate, and 90 μL of kinase reaction buffer (50 μM ATP) was added to each well. After incubation at 30 °C for 30 min, the reactions were washed three times with wash buffer, 100 μL of anti-phospho-mouse IRS-1 S789 monoclonal antibody (AS-4C4) was added, and the plate was incubated at room temperature for 30 min. Then, after washing, 100 μL of HRP-conjugated anti-mouse IgG was added to each well and incubated at room temperature for 30 min. Finally, 100 μL of stop solution was added to each well, and absorbance was measured at 450 nm using a spectrophotometric plate reader.

ATPlite luminescence assay {#Sec9}
--------------------------

Cells were seeded in a 96-well plate at 5 × 10^3^ cells/well for 24 h and then treated with 25 nM ouabain as indicated. The cells were lysed, and ATP fluorescence was measured by following the ATPlite Luminescence Assay System manufacturer's instructions. The relative ATP level was quantified as the fluorescence × 100% in the experimental group and normalized to that of the control group.

Mitochondrial metabolism assay {#Sec10}
------------------------------

Cells were seeded in Seahorse XFp cell culture microplates at 8 × 10^3^ cells/well for 24 h and then treated with ouabain as indicated for another 24 h. The culture medium was replaced with seahorse assay medium, and cells were incubated at 37 °C in a CO~2~-free incubator for 1 h. The assay medium was prepared by adding 100 mM sodium pyruvate, 200 mM *[L]{.smallcaps}*-glutamine and 2.5 M glucose to the Agilent Seahorse XF Base Medium. The seahorse assay was run in an XFp Analyzer System (Agilent Technologies) following the manual provided by the manufacturer. To assess mitochondrial metabolic function, oligomycin (1.0 μM), carbonyl cyanide-*p*-(trifluoromethoxy) phenylhydrazone (FCCP, 1.0 μM), antimycin, and rotenone (0.5 μM) were sequentially injected, and the measurements were recorded after each injection. After measuring the baseline oxygen consumption rate (OCR), the reduction in OCR following oligomycin injection correlates with mitochondrial respiration associated with cellular ATP production. The FCCP-stimulated OCR was used to measure spare respiratory capacity, i.e., the difference between maximal respiration and basal respiration. Rotenone and antimycin A were used to inhibit electron transfer chain (ETC) complexes I and III, respectively, to shut down mitochondrial respiration.

Glycolysis assay {#Sec11}
----------------

Cells were seeded in Seahorse XFp cell culture microplates and treated with ouabain as stated above. The assay medium was prepared by adding 200 mM *[L]{.smallcaps}*-glutamine to the Agilent Seahorse XF Base Medium. The seahorse assay was run in an XFp Analyzer System (Agilent Technologies) following the manufacturer's instructions. To assess the glycolytic function, glucose (10 mM), oligomycin (1.0 μM), and 2-deoxyglucose (2-DG, 50 μM) were sequentially injected, and the measurements were recorded after each injection. After measuring the extracellular acidification rate (ECAR), the increase in ECAR following glucose correlates with the rate of glycolysis under basal conditions. Oligomycin was used to inhibit mitochondrial ATP production and shift energy production to glycolysis. The increase in ECAR following oligomycin reveals the maximal cellular glycolytic capacity. 2-DG was used to inhibit glycolysis through competitive binding to glucose hexokinase. The decrease in ECAR following 2-DG confirms that the ECAR produced is due to glycolysis.

Measurement of glucose consumption {#Sec12}
----------------------------------

Cells were seeded in six-well plates at 5 × 10^5^ cells/well, allowed to attach overnight and then incubated with ouabain as indicated for 24 h. The culture medium was collected for the measurement of glucose concentrations, and the optical density value of each sample was individually measured using a glucose assay kit at 490 nm according to the manufacturer's instructions.

Measurement of lactate production {#Sec13}
---------------------------------

Cells were seeded in six-well plates at 5 × 10^5^ cells/well and treated with ouabain as indicated for 24 h. The cells were then collected and lysed for the detection of lactate production using a lactate assay kit according to the manufacturer's instructions. All values were normalized to the total protein concentration per well \[[@CR13]\].

Statistical analysis {#Sec14}
--------------------

All experiments were repeated at least three times. Statistical analyses were performed using Student's *t* test (between two groups) or one-way ANOVA (within multiple groups) for data comparisons. For IB analysis, one representative result from at least three experiments is shown. Statistical analyses were performed using SPSS 19.0, and differences between the groups were identified as statistically significant at three levels: *P* \< 0.05, *P* \< 0.01, and *P* \< 0.001.

Results {#Sec15}
=======

Both AMPK and Src signaling pathways are rapidly activated by ouabain in human lung cancer and breast cancer cells {#Sec16}
------------------------------------------------------------------------------------------------------------------

Our work has separately demonstrated the activation of AMPK and Src/ERK1/2 signaling pathways within 24 h and 6 h of ouabain treatment, respectively, in human lung cancer cells \[[@CR6], [@CR8]\]. However, whether both pathways are simultaneously activated and whether signal activation is present in other cancer tissue cells remain to be examined. The activation of both pathways was checked by IB analysis within 6 h in A549 lung cancer and MCF7 breast cancer cells after treatment with 25 nM ouabain. The concentration of ouabain falls within the IC~50~ range in either cell line \[[@CR6], [@CR14]\]. Fig. [1a](#Fig1){ref-type="fig"} shows that the simultaneous activation of the AMPK and Src signaling pathways was observed as early as 15 min after treatment, as evidenced by the increase in p-AMPK and its downstream target p-acetyl-CoA carboxylase (p-ACC) \[[@CR15]\], as well as the increased level of p-Src and its downstream target p-ERK1/2. We also examined liver kinase B1 (LKB1) activity, which activates AMPK by phosphorylating Thr172 of the catalytic α-subunit of AMPK \[[@CR16]\], and found that the p-LKB1 level was also increased (Fig. [1a](#Fig1){ref-type="fig"}). Moreover, increased exposure (48 h) to ouabain confirmed the sustained activation of both signaling pathways in MCF7 cells (Fig. [1b](#Fig1){ref-type="fig"}). This finding indicates that both AMPK- and Src-dependent signaling pathways are activated by ouabain.Fig. 1Activation of AMPK and the Src signaling pathway following time-dependent treatment with ouabain (OU) in A549 and MCF7 cells. The cells were treated with 25 nM ouabain in the short term (**a**) and long term (**b**) and then subjected to IB analysis using the respective antibodies, as described in the "Materials and methods" section

Consistently, results from the in vitro AMPK kinase assay also indicated the upregulation of AMPK kinase activity following time-dependent treatment with 25 nM ouabain from 1 to 48 h, with AMPK agonist AICAR serving as a positive control (Fig. [2a](#Fig2){ref-type="fig"}), as it can mimic the effect of AMP on AMPK \[[@CR17]\]. Further quantitative RT-PCR analysis indicated that ouabain affected AMPK activity at the posttranscriptional level, as the compound had little effect on *AMPK* gene expression in both cell types (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 2Effect of ouabain on the activity and the mRNA level of AMPK. The cells were treated with 25 nM ouabain for the indicated time. **a** The cells were subjected to an AMPK kinase assay, as described in the "Materials and methods" section. AICAR (0.5 mM) treatment for half an hour was used as a positive control. Data are expressed as the mean ± S.D. of four independent experiments. **b** Semiquantitative RT-PCR analysis was performed after treatment with ouabain. The intensity of the bands was scanned by ImageJ. Data are expressed as the mean ± S.D. of three independent experiments. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 versus control

AMPK serves as an upstream regulator of Src kinase activation in cancer cells {#Sec17}
-----------------------------------------------------------------------------

Although both the AMPK and Src signaling pathways were activated at the same time in cancer cells, whether both pathways regulate each other remains unknown. Thus, the specific AMPK kinase inhibitor compound C (10 μM), and the Src kinase inhibitor PP2 (10 μM) were used to block the activation of AMPK and Src, respectively, to examine their respective effects. As shown in Fig. [3a](#Fig3){ref-type="fig"}, compound C treatment expectedly blocked the activation of AMPK in A549 cells after exposure to 25 nM ouabain for 6 h. Interestingly, Src activation was also markedly blocked by compound C treatment. In contrast, PP2, along with ouabain treatment, blocked Src activation but had little effect on AMPK signaling. Similar effects were observed in MCF7 cells (Fig. [3a](#Fig3){ref-type="fig"}). Consistently, *AMPK* knockdown with two siRNAs significantly inhibited Src activation (Fig. [3b](#Fig3){ref-type="fig"}). These results indicate that AMPK functions upstream of Src kinase signaling.Fig. 3Effect of specific kinase inhibitors or si-*AMPK* on ouabain- and AICAR-induced AMPK and Src activation. **a** A549 and MCF7 cells were treated with 25 nM ouabain in the presence or absence of 10 μM compound C or 10 μM PP2 for 6 h and then subjected to IB analysis. **b** The cells were transfected with siRNAs targeting AMPK for 48 h and then treated with 25 nM ouabain for 6 h and analyzed by IB. **c** The cells were treated with 0.5 mM AICAR plus 10 μM compound C or 10 μM PP2 for the indicated time and then subjected to IB analysis

We further tested whether the regulation of Src by AMPK activity occurs following treatment with other AMPK activators, such as AICAR. Fig. [3c](#Fig3){ref-type="fig"} shows that AMPK signaling was quickly activated within 1 h following 0.5 mM AICAR treatment in A549 cells. Similarly, Src was activated simultaneously, and inhibition of AMPK activation by compound C significantly inhibited Src activation upon AICAR treatment, while PP2 treatment had little effect on AMPK activation (Fig. [3c](#Fig3){ref-type="fig"}). Similar results were observed in MCF7 cells (data not shown). These data suggest that AMPK, upon activation by either ouabain or AICAR, acts upstream of the Src signaling pathway in cancer cells.

Ouabain-induced ATP depletion activates AMPK {#Sec18}
--------------------------------------------

AMPK is a well-known energy sensor involved in maintaining energy homeostasis in response to metabolic stress, including the increase in AMP/ATP ratio during nutrient deficiency \[[@CR16]\]. We next checked whether AMPK activation correlates with changes in ATP. As shown in Fig. [4a](#Fig4){ref-type="fig"}, intracellular ATP levels in both A549 and MCF7 cells were markedly decreased in a time-dependent manner at 24 h following 25 nM ouabain treatment. Furthermore, the addition of ATP (100 μM) to the medium blocked AMPK activation, indicating that ouabain-induced AMPK activity is affected by intracellular ATP alterations (Fig. [4b](#Fig4){ref-type="fig"}).Fig. 4Ouabain depletes intracellular ATP levels, and the addition of ATP blocks AMPK activation. **a** Cells were treated with 25 nM ouabain for the indicated time, and the ATP levels were measured with the ATPlite Luminescence Assay System as described in the "Materials and methods" section. \*\**P* \< 0.01; \*\*\**P* \< 0.001 versus control. **b** The cells were treated with ouabain in the presence or absence of ATP (100 μM) for the indicated time and subjected to IB analysis

Ouabain affects mitochondrial respiration and glycolysis in cancer {#Sec19}
------------------------------------------------------------------

Dysregulated metabolism is one of the hallmarks of cancer \[[@CR18]\]. Both aerobic glycolysis (Warburg effect) and mitochondrial OXPHOS may operate simultaneously to produce energy in cancer cells \[[@CR19], [@CR20]\]. We next checked whether energy depletion results from altered metabolism following ouabain treatment. The effect of ouabain on mitochondrial OXPHOS and glycolysis was tested using the Seahorse analyzer by measuring the OCR and ECAR, respectively \[[@CR21]\]. The baseline respiration, ATP production, maximum respiration, and spare respiratory capacity are critical parameters demonstrating mitochondrial OXPHOS measured by the Seahorse Mito Stress kit after sequential compound injections. As seen in Fig. [5a, b](#Fig5){ref-type="fig"}, the OCR parameters were dose-dependently reduced in A549 cells by ouabain treatment, with a high concentration (25 nM) causing a significant effect on baseline respiration and ATP production. A similar reduction in the OCR was observed in MCF7 cells (Supplementary Fig. [1a, b](#MOESM1){ref-type="media"}). This finding indicates that mitochondrial OXPHOS is greatly reduced by ouabain in cancer.Fig. 5Regulation of mitochondrial respiration and glycolysis by ouabain in A549 cells. **a**, **b** A549 cells were treated with ouabain as indicated for 24 h, and mitochondrial respiration was measured as described in the "Materials and methods" section. \**P* \< 0.05; \*\**P* \< 0.01. **c**, **d** The cells were treated with ouabain as indicated for 24 h, and the glycolytic function of mitochondria was measured as described in the "Materials and methods" section. \*\**P* \< 0.01. **e**, **f** A549 cells were treated with ouabain as indicated for 24 h and analyzed with a lactate assay and glucose assay. \**P* \< 0.05; \*\*\**P* \< 0.001 versus control

To determine whether AMPK activation occurs before or after OXPHOS reduction, compound C was added simultaneously with ouabain, and the OCR was subsequently measured. As shown in Fig. [6a](#Fig6){ref-type="fig"}, cotreatment with compound C did not restore mitochondrial respiration but instead reduced OCR levels, confirming that AMPK was activated following ouabain-reduced OXPHOS.Fig. 6Effect of compound C and AICAR on mitochondrial respiration and glycolysis. **a** A549 cells were treated with 25 nM ouabain in the presence or absence of 10 μM compound C for 24 h, and mitochondrial respiration was measured. \**P* \< 0.05 versus control. ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001 versus 25 nM ouabain. **b**, **c** A549 and MCF7 cells were treated with 0.5 mM AICAR for 24 h, and assessed by lactate and glucose assays \**P* \< 0.05; \*\*\**P* \< 0.001 versus control

Furthermore, 25 nM ouabain treatment greatly reduced glycolysis in A549 cells, as demonstrated by the decreased ECAR, as well as by the decreased lactate production and glucose uptake (Fig. [5c--f](#Fig5){ref-type="fig"}). However, little effect of the compound was observed on ECAR, and 25 nM ouabain treatment even slightly increased lactate production and glucose uptake in MCF7 cells (Supplementary Fig. [1](#MOESM1){ref-type="media"}c--[f](#MOESM1){ref-type="media"}). We further tested whether the AMPK activator AICAR exerts a differential effect on glycolysis in both cell lines. Interestingly, glycolysis was greatly decreased in A549 cells but slightly increased in MCF7 cells following AICAR treatment, as measured by lactate production and glucose consumption (Fig. [6b, c](#Fig6){ref-type="fig"}). This finding indicates that AMPK activation may exert differential effects on glycolysis depending on the cancer cell type.

Discussion {#Sec20}
==========

NKA-targeted therapy has become a valid anticancer strategy since abnormal NKA expression is closely correlated with cancer initiation, progression, and metastasis \[[@CR22]\]. In addition to the regulatory role of ion homeostasis played by NKA, the pump is known to function as a receptor that regulates the signal transduction pathway. Ouabain, a well-established NKA inhibitor, has potent anticancer effects in many tissues. Ouabain binds to the α-subunit of NKA and inhibits its ion exchange pump activity. Furthermore, ouabain can initiate the receptor function of NKA, leading to the activation of Src tyrosine kinase and downstream Ras and MAPK (including ERK1/2) cascade activation, as well as various other biological functions \[[@CR1], [@CR2]\]. In our previous study, we showed that ouabain activates AMPK and consequently inhibits mTOR activation, leading to autophagic cell death in lung cancer cells, which contribute to the cytotoxicity of the compound \[[@CR8]\]. Furthermore, ouabain-induced activation of the Src-ERK1/2 signaling pathway also positively regulates autophagic cell death \[[@CR6]\]. In this work, we further demonstrate that (1) AMPK serves as an upstream regulator of Src kinase activation in cancer cells upon ouabain treatment, (2) AMPK activation responds to ouabain-induced ATP depletion, and (3) ouabain greatly reduces mitochondrial respiration while exerting differential cancer cell type-dependent effects on glycolysis.

AMPK is a heterotrimer consisting of a catalytic α-subunit and regulatory β- and γ-subunits; the phosphorylation of AMPKα Thr172 is required for the activation of the complex \[[@CR12]\]. AMPK plays a pivotal role in many metabolic stress responses and possesses dual tumor suppressing and promoting functions in cancer \[[@CR23]\]. In this work, we found that ouabain triggers the rapid activation of AMPK activity as early as 15 min, which is much earlier than the 2 h timeframe in our previous study \[[@CR8]\]. The enhanced AMPK activity is evidenced by the increase in phosphorylation of AMPKα Thr172 and the increase in phosphorylation of ACC, a direct AMPK target protein \[[@CR15]\], by IB analysis. AMPK activity was also confirmed in the in vitro kinase assay. Given that LKB1 is one of the primary kinases that phosphorylates AMPK \[[@CR24]\], our data also confirm the increase in LKB1 activity upon ouabain treatment, indicating that the phosphorylation of AMPK is activated, at least partially, by LKB1.

Although we identified ouabain as an AMPK activator at the nanomolar level in cancer in our present and previous work, the compound was previously reported to inhibit AMPK activity at micromolar doses in rat parotid acinar cells either with or without carbachol stimulation \[[@CR25]\]. This discrepancy may result from the large differences with regard to the drug concentration and cellular contexts in the two studies, given that CGs are well known to initiate diverse signaling and biological effects at various concentrations in many cell types. Consistent with our data, other compounds in the CGs family, such as proscillaridin A, bufalin, and digitoxin, have been reported to induce AMPK activation at the nanomolar level in either cancer cell lines or normal human foreskin fibroblast cells, contributing to apoptosis or autophagy \[[@CR26]--[@CR29]\]. Interestingly, AMPK activation by proscillaridin A has been suggested to be correlated with the elevation of the intracellular Ca^2+^ level, as the interruption of the NKA pump activity by CGs normally stimulates Na^+^/Ca^2+^ exchange, leading to an increase in the calcium ion level \[[@CR26]\]. The increased Ca^2+^ concentration can consequently stimulate calmodulin-dependent kinase kinase β, which is another positive upstream regulator of AMPK \[[@CR12]\]. Although the intracellular Ca^2+^ concentration was not assessed in the present work, the role of Ca^2+^ in AMPK activation may not be excluded, given the universal role of ouabain as an NKA inhibitor. Notably, CGs have recently been reported to cause selective anticancer effects in STK11 (LKB1) mutant cells rather than in STK11 wild-type cells, and AMPK activity is quickly inhibited by 100 nM digoxin treatment in A549 lung cancer cells \[[@CR30]\]. This work suggests that AMPK activation may provide a resistance mechanism to the effects of CGs, given that functional STK11-AMPK signaling is important for cancer cells to overcome stress responses induced by anticancer agents \[[@CR31]\]. These data reflect the complicated responses of AMPK upon CGs treatment in cancer cells under different research conditions.

Here, we report that AMPK functions upstream of the Src signaling pathway upon ouabain or AICAR treatment in A549 and MCF7 cancer cells. Consistent with our findings, metformin has been shown to activate the AMPK-Src-Cbl axis pathway, and compound C blocks Src activation in 3T3-L1 preadipocytes \[[@CR32]\]. Another study also showed that AMPK contributes to Src activation in endothelial cells or THP-1 monocytes \[[@CR9], [@CR33]\]. However, there are reports showing that AMPK activation by either metformin, ONOO^−^, or estrogen is mediated by Src activation \[[@CR10], [@CR11], [@CR34]\]. Furthermore, Src controls AMPK activity by signaling through PKCα, PLCγ, and LKB1 in certain cancer cell lines, including L-HF1, BP-HF-1, OVCAR3, and A431 \[[@CR35]\]. These findings indicate that the cross-regulation between AMPK and Src pathway is complicated and may be cell type specific. Although Src activation is associated with the interaction with the NKA pump following CGs binding \[[@CR1], [@CR2]\], and Src interacts with AMPK \[[@CR32]\], little is known about the correlation of AMPK with NKA, which is worthy of further research.

Growing evidence indicates that OXPHOS, along with aerobic glycolysis, is a common metabolic phenotype in cancer \[[@CR20], [@CR36]\]. OXPHOS is an efficient mitochondrial metabolism for the generation of ATP by the tricarboxylic acid cycle. Our findings suggest that ouabain-induced AMPK activation responds to ATP depletion from impaired OXPHOS, based on the fact that time-dependent depletion of ATP levels occurs in parallel with the timing of AMPK activation and that supplementation with ATP blocks AMPK activity (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}). Consistent with the positive regulatory role of AMPK in OXPHOS through the stimulation of mitochondrial biogenesis \[[@CR37]\], cotreatment with the AMPK inhibitor compound C and ouabain further inhibited OXPHOS (Fig. [6a](#Fig6){ref-type="fig"}). The ATP-depleting effect of ouabain confirms our previous observation and indicates that ouabain induces starvation-associated molecular signaling \[[@CR8]\]. However, how ouabain impacts metabolism remains elusive. It is possible that ouabain may target ETC complexes to inhibit OXPHOS, much like metformin does \[[@CR21], [@CR38]\], although further experiments are required to test this hypothesis.

Aerobic glycolysis is a special metabolism phenotype in cancer \[[@CR39]\]. The impairment of OXPHOS by anticancer drugs that activate AMPK always boosts glycolysis \[[@CR21], [@CR40]\]. However, we found that ouabain treatment decreases glycolysis in A549 cells but has a marginal effect on glycolysis in MCF7 cells. Interestingly, the AMPK activator AICAR similarly induces different metabolic effects on glycolysis in A549 and MCF7 cells. This finding indicates that the AMPK activating-agent-induced metabolic response may vary depending on the cancer cell type. AMPK negatively regulates glycolysis by inhibiting HIF-1α, a key regulator of glycolysis \[[@CR41]\]; thus, the inhibition of glycolysis in A549 cells may occur in response to AMPK activation by ouabain. However, the possibility that ouabain directly inhibits glycolysis may not be excluded, as CGs are reported to be capable of inhibiting HIF-1α synthesis \[[@CR5]\]. Thus, the complicated metabolic response to ouabain may reflect a combination of the differential metabolic plasticities in various cancer types and the nature of the class of CGs \[[@CR19]\].

Taken together, these results demonstrate the detailed regulation between cancer metabolism and AMPK activation by ouabain. The altered cell metabolism may contribute to the cancer cell cytotoxicity of ouabain.
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